Genome-wide variation in cell-free DNA end-motif entropy predicts immunotherapy response in head and neck cancer.

Saved in:
Bibliographic Details
Title: Genome-wide variation in cell-free DNA end-motif entropy predicts immunotherapy response in head and neck cancer.
Authors: Bandaru R; Department of Biochemistry and Molecular Genetics, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.; Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois, USA., Fu H; Department of Biochemistry and Molecular Genetics, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.; Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois, USA., Zheng H; Division of Human Genetics, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA., Liang J; Department of Biochemistry and Molecular Genetics, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.; Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois, USA., Wang L; Department of Biochemistry and Molecular Genetics, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.; Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois, USA., Gulati S; Division of Hematology/Oncology, and., Hinrichs BH; Department of Pathology, University of Cincinnati, Cincinnati, Ohio, USA., Teng M; Department of Biostatistics and Bioinformatics, Moffitt Cancer Center, Tampa, Florida, USA., Zhang B; Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.; Division of Biostatistics and Epidemiology, Cincinnati Children's Hospital Medical Center, Ohio, USA., Kocherginsky M; Department of Preventive Medicine, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA., Lin DC; Center for Craniofacial Molecular Biology, Herman Ostrow School of Dentistry, and Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, California, USA., Hildeman DA; Division of Immunobiology, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA., Worden FP; University of Michigan Cancer Center, Ann Arbor, Michigan, USA., Old M; Department of Otolaryngology, Ohio State University, Columbus, Ohio, USA., Dunlap NE; Department of Radiation Oncology, University of Louisville, Louisville, Kentucky, USA., Kaczmar JM; Division of Hematology/Oncology, Medical University of South Carolina, Charleston, South Carolina, USA., Gillison ML; The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., El-Gamal D; Division of Hematology/Oncology, and., Wise Draper T; Division of Hematology/Oncology, and., Liu Y; Department of Biochemistry and Molecular Genetics, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.; Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois, USA.
Source: The Journal of clinical investigation [J Clin Invest] 2026 May 19; Vol. 136 (13). Date of Electronic Publication: 2026 May 19 (Print Publication: 2026).
Publication Type: Journal Article; Clinical Trial, Phase II; Multicenter Study
Journal Info: Publisher: American Society for Clinical Investigation Country of Publication: United States NLM ID: 7802877 Publication Model: eCollection Cited Medium: Internet ISSN: 1558-8238 (Electronic) Linking ISSN: 00219738 NLM ISO Abbreviation: J Clin Invest Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1558-8238
DOI:10.1172/JCI196284